Analysis Highlights Multi-Organ Adverse Events from Cancer Immunotherapies – FDA
FDA shared a post on LinkedIn:
“A descriptive analysis by FDA clinical reviewers using clinical trial data submitted to the agency aimed to uncover insights into the multi-organ patterns of adverse events related to the use of immune system therapies for patients with cancer. The study’s findings may help healthcare providers understand, predict and manage patients experiencing adverse events associated with immunotherapies.
The analysis was published online as part of the American Association for Cancer Research 2025 Annual Meeting.”
Quoting Foundation for Autoimmune Cancer Support (FACS-ASPIRE)‘s post:
“Such important work and amazing to see the FDA dive into immune related adverse events as an overview to have a better understanding the risk profile so we can maximize efficacy of IO.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023